Oncology Conference update

Coming soon! Highlights from ESMO 2025

Experts are joining us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Dr Herbert H. Loong

Prof. Viktor Grünwald

Prof. Thomas Powles

Dr Elisa Agostinetto

Prof. Nicoletta Colombo

Dr Elizabeth Smyth

Publication Date

Oct 2025

Summary and next episodes

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

Full name*

Email*

My therapeutic area is*

I accept the terms and conditions.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Programme summary

Duration 1 MIN
Language(s)

Watch the video now

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Summary and next episodes

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Prof. Viktor Grünwald will join us at ESMO 2025 to share his insights into how new data presented at the meeting may impact clinical practice.

Prof. Grünwald is expected to report on advanced renal cell carcinoma data from the LenCabo, KEYMAKER-U03 and CLEAR studies and may also review the use of [68 Ga]Ga-DPI-4452 for staging of disease.

LenCabo: A randomised, phase 2, multicentre trial of lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC that progressed on PD-1 immune checkpoint inhibition. Hahn A, et al.  Abstract LBA94, ESMO 2025
KEYMAKER-U03: First-line pembrolizumab-based regimens for advanced ccRCC: substudy 03A. Suarez Rodriguez C, et al. Abstract LBA96, ESMO 2025
CLEAR: Final analysis of lenvatinib + pembrolizumab vs sunitinib in patients with aRCC with or without bone metastases in CLEAR. Porta CG, et al. Abstract 2603P, ESMO 2025
CAIX PET/CT: [68Ga]Ga-DPI-4452 (CAIX) PET/CT for staging of patients with ccRCC. Küper AT, et al. Abstract 2597MO, ESMO 2025

Come back soon to get Prof. Grünwald's expert view on what these data could mean for RCC management, and to view his accompanying slides for more detailed insights.

Understand the latest clinical trial data in advanced RCC and potential implications for patient management
Recognise and determine the appropriate placement and combination of therapies for the treatment of advanced RCC

Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications.

Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers.

Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).

Prof. Viktor Grünwald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Astellas, BMS, Debiopharm, Gilead, Eisai, Ipsen, Johnson & Johnson, Merck, MSD, Novartis/AAA, Oncorena, Pfizer, Telix Pharmaceutical, Recordati, Roche and Synthekine.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

We're excited to announce that Prof. Thomas Powles, renowned Professor of GU Oncology and Director at Bart's Cancer Centre, London, will be joining us at ESMO 2025 to share an update on bladder and prostate cancers.

Prof. Powles will review the latest data as they are presented at the congress, and reveal his expert views on the potential impact on clinical practice.

Come back soon to discover which studies Prof. Powles selects to report on and get his key takeaways from this major oncology event.

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

Full name*

Email*

My therapeutic area is*

I accept the terms and conditions.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Programme summary

Duration MIN
Language(s)

Share this programme

This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.

Supporter Acknowledgement

Endorsement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Brought to you by

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Brought to you by

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Summary and next episodes

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Dr Herbert Loong is joining us in Berlin to share his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025.

Dr Loong is expected to review data from the following studies:

OptiTROP-Lung04: Sacituzumab tirumotecan vs platinum-based chemotherapy in EGFR-mutated NSCLC following progression on EGFR-TKIs: results from a randomised, multi-centre, phase 3 study. Zhang L, et al. Abstract LBA5, ESMO 2025

SOHO-01: Sevabertinib (BAY 2927088) in advanced HER2-mutant NSCLC. Le X, et al. Abstract LBA75, ESMO 2025

Beamion LUNG 1: Zongertinib as 1^st line treatment in patients with advanced HER2-mutant NSCLC. Popat S, et al. Abstract LBA74, ESMO 2025

LOXO-RAS-20001: Intracranial efficacy of olomorasib, a 2^nd generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases. Cassier P, et al. Abstract 1846MO, ESMO 2025

FURMO-003: Phase 2 study of firmonertinib in patients with previously treated advanced or mNSCLC with EGFR Exon 20 insertion mutations. Liu Y, et al. Abstract 1848MO, ESMO 2025

Check back soon to watch Dr Loong's short video update, get his key clinical takeaways, and download the accompanying slide set for more detailed insights.

Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC

Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.

Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.

Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

Dr Herbert H. Loong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Amgen, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Eli-Lilly, George Clinical, Guardant Health, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

Full name*

Email*

My therapeutic area is*

I accept the terms and conditions.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Programme summary

Duration MIN
Language(s)

Share this programme

This educational programme is supported by an Independent Educational Grant from Bayer.

Supporter Acknowledgement

This educational programme is supported by an Independent Educational Grant from Bayer.

Endorsement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts

Brought to you by

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts

Brought to you by

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Summary and next episodes

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Dr Elisa Agostinetto will join us in Berlin to share her perspectives on the latest breast cancer data as they emerge from ESMO 2025.

Dr Agostinetto is expected to review data from the following studies:

monarchE: Primary overall survival results of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer. Johnston S.R, et al. Abstract LBA13, ESMO 2025
DESTINY-Breast05: Trastuzumab deruxtecan vs trastuzumab emtansine in patients with high-risk HER2+ primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis. Geyer C.E, et al. Abstract LBA1, ESMO 2025
DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs SOC for high-risk HER2+ early breast cancer. Harbeck N, et al. Abstract 291O, ESMO 2025
ASCENT-03: Primary results from a randomised phase 3 study of sacituzumab govitecan vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer who are unable to receive PD-(L)1 inhibitors. Cortés J.C, et al. Abstract LBA20, ESMO 2025

How will these data impact clinical practice? Come back soon to find out!

Dr Elisa Agostinetto is a medical oncologist and leading researcher in the field of breast cancer. She received her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles.

Dr Elisa Agostinetto has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Sandoz, AstraZeneca; support for conference attendence from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca and a research grant to her institution from Gilead.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Prof. Nicoletta Colombo is joining us at ESMO 2025 to share her insights into gynecological cancer data as they are presented at the congress.

Prof. Colombo is expected to report on endometrial cancer and ovarian cancer, and may review the following key studies:

ENGOT-ov65/KEYNOTE-B96: Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomised double-blind phase 3 study. Colombo N, et al. Abstract LBA3, ESMO 2025
AtTEnd/ENGOT-EN7: Final overall survival results from the randomised double-blind phase 3 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Barrentina Ginesta M.P, et al. Abstract LBA39, ESMO 2025
REJOICE-Ovarian01: Raludotatug deruxtecan in patients with platinum-resistant ovarian cancer: primary analysis of the phase 2 dose-optimisation part of REJOICE-Ovarian01. Ray-Coquard I.L, et al. Abstract LAB42, ESMO 2025

Check back soon to watch the video and discover how these developments could change clinical practice!

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

Full name*

Email*

My therapeutic area is*

I accept the terms and conditions.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

Endorsement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

OBSTETRICS & GYNECOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Eisai Europe Ltd, Aspivix and Novo Nordisk.

Meet the experts Independent IME approved

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts

Brought to you by

OBSTETRICS & GYNECOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Eisai Europe Ltd, Aspivix and Novo Nordisk.

Meet the experts Independent IME approved

Summary and next episodes

Gastric and gastroesophageal cancer update

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

We're looking forward to Dr Lizzy Smyth joining us in Berlin to share her perspectives on the latest gastric and gastroesophageal data presented at ESMO 2025.

Dr Smyth is expected to review key data from the following studies:

MATTERHORN: Event-free survival with pathological outcomes: a randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction adenocarcinoma. Tabernero J, et al. Abstract LBA81, ESMO 2025
LEAP-014: Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomised phase 3 LEAP-014 study. Sun J-M, et al. Abstract LBA79, ESMO 2025
SKYSCRAPER-07: A phase 3, randomised study of atezolizumab with or without tiragolumab in patients with unresectable esophageal squamous cell carcinoma that has not progressed following definitive concurrent chemoradiotherapy. Chau I, et al. Abstract 2094O, ESMO 2025

Come back soon to find out whether Dr Smyth thinks these new data will change clinical practice.

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants from Bristol-Myers Squibb and Astra Zeneca, personal fees from Amgen, Astellas, Astra Zeneca, Beigene, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Mirati, Novartis, Pfizer, Viracta, and Zymeworks. Chair of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group (2024–26), and has been trustee of the UK & Ireland Oesophagogastric Cancer Group since 2022; and is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

Full name*

Email*

My therapeutic area is*

I accept the terms and conditions.

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

Endorsement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.

Meet the experts

Brought to you by

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Programme summary

Duration MIN
Language(s)

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Brought to you by

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.

Meet the experts

Brought to you by

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

Video podcast

Oncology Endocrinology Rare diseases

Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts

Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)

Endorsed by

Downloadable
Resources
21 MIN
Oct 2025

Educational programme supported by an Independent Educational Grant from ITM.

Interactive Patient Case Video (IPCV)

Oncology

Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts

Prof. Gunhild von Amsberg

Endorsed by

25 MIN
Sep 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca

Conference update

Oncology

Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer

Experts

Dr Devika Das

Endorsed by

Downloadable
Resources
5 MIN
Sep 2025

Educational programme supported by an Independent Educational Grant from Bayer.

Video podcast

Oncology

Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts

Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard

Endorsed by

Downloadable
Resources
5 MIN
Sep 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.

Speed ReadVideo overview

Oncology

Managing ADC toxicities in HER2+ metastatic breast cancer

Spotlight on nausea and vomiting

Experts

Dr Sara Tolaney

Endorsed by

Downloadable
Resources
6 MIN
Aug 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.

Speed ReadVideo overview

Oncology

The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Experts

Prof. Chiara Cremolini

Downloadable
Resources
4 MIN
Jul 2025

Explore all programmes

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Coming soon! Highlights from ESMO 2025

Experts are joining us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Dr Herbert H. Loong

Prof. Viktor Grünwald

Prof. Thomas Powles

Dr Elisa Agostinetto

Prof. Nicoletta Colombo

Dr Elizabeth Smyth

Publication Date

I agree that this educational programme:

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

I agree that this educational programme:

Programme summary

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Programme summary

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

I agree that this educational programme:

Prof. Viktor Grünwald Medical Oncologist University Hospital Essen Germany (DE)

Prof. Viktor Grünwald

Biography

Disclosures

I agree that this educational programme:

Prof. Thomas Powles Medical Oncologist Bart's Cancer Centre United Kingdom (GB)

Prof. Thomas Powles

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

I agree that this educational programme:

Programme summary

Share this programme

Supporter Acknowledgement

Endorsement

I agree that this educational programme:

Brought to you by

Brought to you by

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Programme summary

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Brought to you by

Programme summary

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Brought to you by

Brought to you by

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

I agree that this educational programme:

Dr Herbert H. Loong Clinical Assoc. Prof. in Department of Clinical Oncology The Chinese University of Hong Kong China (CN)

Dr Herbert H. Loong

Biography

Disclosures

This programme is coming soon... sign up below and we'll let you know as soon as it goes fully live!

I agree that this educational programme:

Programme summary

Share this programme

Supporter Acknowledgement

Endorsement

I agree that this educational programme:

Brought to you by

Brought to you by

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Programme summary

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Brought to you by

Brought to you by

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

I agree that this educational programme:

Dr Elisa Agostinetto Medical Oncologist and Research Fellow Institut Jules Bordet Belgium (BE)

Dr Elisa Agostinetto

Biography

Disclosures

I agree that this educational programme:

Prof. Nicoletta Colombo Medical Oncologist University of Milan Italy (IT)

Prof. Nicoletta Colombo